Abstract
Purpose: Vigabatrin (Sabril), a drug that blocks GABA transaminase, has been used in the treatment of epilepsy since 1989. There have been reports of irreversible constriction of the visual field in adult patients related to vigabatrin (VGB) therapy, resulting in reduced VGB usage in adults. Although used as a second or third line agent in adults, in children it is often considered as a first line treatment for several subgroups of seizures in spite of there being no way, in the majority of cases, to monitor visual fields. Some of these children have a pre-existing visual field defect as part of their primary disorder. We aimed to identify whether visual field loss due to VGB was occurring in our hospital.
Methods: We have studied the results of ophthalmic examination in 14 children on VGB at Great Ormond Street Hospital who were able to perform Goldmann visual fields.
Results: Ten of the 14 patients had constriction of their visual fields attributed to VGB. In addition there were 2 patients with suspicious visual field defects thought to be due to VGB. There was pre-existing visual pathway damage in 4 cases and in 2 of these optic disc pallor increased in association with constricted visual fields. However, the optic discs were normal in 7 patients in spite of visual field constriction. Visual acuity was generally normal in spite of gross visual field constriction.
Conclusion: We believe that VGB should be used with great caution where there is pre-existing visual pathway damage. In other cases the benefits should be considered in relation to the risks, which include irreversible visual field damage. At present visual fields can only be monitored by perimetry, which is often not possible in children with epilepsy.
Similar content being viewed by others
Article PDF
References
Coulter DA . Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997;12(Suppl 1):S2–9.
Natsch S, Hekster YA, Keyser A, Deckers CL, Meinardi H, Renier WO . Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Safety 1997;17:228–40.
Leach PJ, Brodie MJ . Tiagabine. Lancet 1998;351:203–7.
Gibson JP, Yarrington JT, Loudy DE, et al. Chronic toxicity studies with vigabatin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225–38.
Harding GF . Severe persistent visual field constriction associated with vigabatrin. Benefit:risk ratio must be calculated for individual patients. BMJ 1998;316:232–3.
Reynolds EH . Gamma-vinyl GABA (vigabatrin): clinical experience in adult and adolescent patients with intractable epilepsy. Epilepsia 1992;33(Suppl 5);S30–4; discussion S34–5.
Faedda MT, Giallonardo AT, Marchetti A, Manfredi M . Terepia con vigabatrin nelle epilessie parziali resistenti. (Vigabatrin therapy for resistant partial epilepsies.) G Neuropsicofarmacol 1993;15:105–8.
Eke T, Talbot JF, Lawden MC . Severe persistent visual field constriction associated with Vigabatrin. BMJ 1997;314:180–1.
Anon. Does vigabatrin affect the eye? Pharm J 1997;258:120.
Mackenzie R, Klistorner A . Severe persistent visual field constriction associated with Vigabatrin: asymptomatic as well as symptomatic defects occur with Vigabatrin [letter]. BMJ 1998;31:233.
Wilson EA, Brodie MJ . Severe persistent visual field constriction associated with Vigabatrin. Chronic refractory epilepsy may have a role in causing these unusual lesions. BMJ 1997;314:1693.
Blackwell N, Hayllar J, Kelly G . Severe persistent visual field constriction associated with Vigabatrin: patients taking Vigabatrin should have regular VF examination. BMJ 1997;314:1694.
Harding G, Wild J, Robertson K, Edson E, Barber C, Lawden M, et al. Electrooculography, EOGs, multi-focal ERGs and VEPs in epileptic patients showing visual field disorders. Electroencephalogr Clin Neurophysiol 1997;103:96.
Wong IC, Mawer GE, Sander JW . Severe persistent visual field constriction associated with Vigabatrin: reaction may be dose dependent [letter; comment]. BMJ 1997;314:1693–4.
Krauss GL, Johnson MA, Miller NR . Vigabatrin associated retinal cone system dysfunction: electroretinographic and ophthalmological findings. Neurology 1998;50:614–8.
Rao GP, Fat FA, Kyle G, Leach JP, et al. Study is needed of visual field defects associated with any long term antiepileptic drug [letter]. BMJ 1998;317:206.
Ruether K, Pung T, Kellner U, et al. Electrophysiologic evaluation of a patient with peripheral visual field constriction associated with Vigabatrin [letter]. Arch Ophthalmol 1998;116:817–9.
Acheson JF, Wearne MJ, Graham EM, Sanders MD . Vigabatrin-associated visual failure: analysis of 4 cases presenting with major visual field defects. Poster presentation at the Oxford Congress of Ophthalmology, 1999.
Mackey DA, Craig JE, Gioulekas J, Cooper RL . Vigabatrin associated visual field loss resembling low tension glaucoma. Invest Ophthalmol Vis Sci 1999;40:S63–339.
Versino M, Veggiotti P . Reversibility of vigabatrin-induced visual-field defect. Lancet 1999;354:486.
Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A . Symptomatic and asymptomatic visual loss in patients taking Vigabatrin. Ophthalmology 1999;106:1792–8.
Wilton LV, Stephens MDB, Mann RD . Visual field defect associated with vigabatrin: observational cohort study. BMJ 1999;139:1165–6.
Roubertie A, Bellet H, Echenne B . Vigabatrin-associated retinal cone system dysfunction [letter; comment]. Neurology 1998;51:1779–81.
Beren R, Currie J, Sandbach J, Plunkett M . Visual field restriction with new anti-epileptic medications [abstract]. European Epilepsy Society, Warsaw, May 1998.
Baulac M, Nordmann J-P, Lanoe Y. Severe visual-field constriction and side effects of GABA-mimetic antiepileptic agents. Lancet 1998;352:546.
Kalvianen R, Nousiainen I, Mantyjarvi M, Riekkinen Sr PPJ . Absence of concentric visual fields in patients with long-term Tiagabine monotherapy. Neurology 1999;52(Suppl 2):P03.118.
Harding GFA . Severe persistent visual field constriction associated with Vigabatrin: four possible explanations exist [letter, comment]. BMJ 1997;314:1694.
Hoechst Marion Roussel Australia. Guidelines for clinical practise. Visual field constriction and Vigabatrin (Sabril) 1998.
Appleton RE . Guidelines may help in prescribing vigabatrin. BMJ 1998;317:1322.
Osborne JP, Edwards SW, Hancock E, Lux AL, O'Callaghan F, Johnson T, et al. Infantile spasms and vigabatrin: study will compare effects of drugs [letter]. BMJ 1999;318:56–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Russell-Eggitt, I., Mackey, D., Taylor, D. et al. Vigabatrin-associated visual field defects in children. Eye 14, 334–339 (2000). https://doi.org/10.1038/eye.2000.83
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1038/eye.2000.83